Clemens Krepler, MD

Executive Director
Merck & Co., Inc., Rahway, NJ, USA, United States

Presentation(s):

• 54: Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study

  Friday, March 24, 2023
  1:49 PM – 2:01 PM

  Disclosure information not submitted.